Renovacor, Inc.
RCOR
New York Stock Exchange Arca3.20
USD
+0.15
- -
CIK
0001799850
ISIN
US75989E1064
CUSIP
75989E106
Return %
Stock
S&P500
1Y
-43.56
26.53
3Y
-67.38
76.60
5Y
-67.38
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- PO Box 8142 Greenwich CT United States of America 06836
- IPO Date
- Jun 22, 2020
- CIK
- 0001799850
- Website
- renovacor.com
- Similar Companies
- Business
- Renovacor, Inc. (NYSE: RCOR) is a preclinical-stage biotechnology company that develops adeno-associated virus (AAV)-based gene therapies targeting BAG3 gene mutation-associated diseases, with a primary focus on genetically-driven cardiovascular conditions including BAG3-associated dilated cardiomyopathy (DCM); its lead product candidate, REN-001, is a recombinant AAV9-based gene therapy designed to deliver a functional BAG3 gene to cardiomyocytes to slow or halt disease progression; additional preclinical programs explore AAV therapies for arrhythmogenic cardiomyopathy via targets such as PKP2, DSP, and DSG2, as well as BAG3-mediated central nervous system disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company serves patients with rare, monogenic heart failure disorders lacking approved disease-modifying treatments and operates primarily in the United States through research collaborations, including with the University of Utah. In December 2022, Rocket Pharmaceuticals, Inc. completed its acquisition of Renovacor in an all-stock transaction valued at approximately $53 million, integrating REN-001 and related assets into Rocket's pipeline to expand its AAV-based cardiac gene therapy leadership; Renovacor shares ceased trading on the NYSE following the deal, which added about $38 million in cash and extended Rocket's runway into mid-2024; prior to the acquisition, Renovacor had gone public via a 2021 reverse merger with Chardan Healthcare Acquisition 2 Corp., raising $95.1 million, and reported preclinical advancements such as effective cardiac transduction data from REN-001 pig studies published in JACC: BTS.
SHAREHOLDER ALERT: Weiss Law Reminds LFG, ECOM, LOTZ, and RCOR Shareholders About Its Ongoing Investigations
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCOR, SMBC, TALO
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STOR, RCKT, RCOR, FCRD